Castlekeep Investment Advisors LLC Sells 6,901 Shares of Cencora, Inc. $COR

Castlekeep Investment Advisors LLC trimmed its holdings in Cencora, Inc. (NYSE:COR) by 89.3% in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 828 shares of the company’s stock after selling 6,901 shares during the quarter. Castlekeep Investment Advisors LLC’s holdings in Cencora were worth $248,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of COR. DAVENPORT & Co LLC increased its holdings in Cencora by 12.8% in the 1st quarter. DAVENPORT & Co LLC now owns 6,214 shares of the company’s stock worth $1,728,000 after buying an additional 705 shares in the last quarter. Keybank National Association OH increased its holdings in Cencora by 1.7% in the 1st quarter. Keybank National Association OH now owns 8,034 shares of the company’s stock worth $2,234,000 after buying an additional 133 shares in the last quarter. Pinnacle Financial Partners Inc bought a new stake in shares of Cencora during the 1st quarter valued at about $253,000. Private Trust Co. NA grew its stake in shares of Cencora by 2.5% during the 1st quarter. Private Trust Co. NA now owns 1,933 shares of the company’s stock valued at $538,000 after purchasing an additional 47 shares during the period. Finally, D.A. Davidson & CO. grew its stake in shares of Cencora by 3.4% during the 1st quarter. D.A. Davidson & CO. now owns 1,909 shares of the company’s stock valued at $531,000 after purchasing an additional 63 shares during the period. 97.52% of the stock is currently owned by institutional investors.

Cencora Stock Down 1.1%

COR stock opened at $337.60 on Friday. Cencora, Inc. has a twelve month low of $223.92 and a twelve month high of $350.46. The company has a quick ratio of 0.53, a current ratio of 0.90 and a debt-to-equity ratio of 3.64. The stock has a market cap of $65.45 billion, a P/E ratio of 34.73, a PEG ratio of 1.56 and a beta of 0.63. The business’s 50-day moving average price is $308.09 and its 200-day moving average price is $297.11.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, August 6th. The company reported $4.00 earnings per share for the quarter, beating analysts’ consensus estimates of $3.79 by $0.21. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The firm had revenue of $80.66 billion for the quarter, compared to analysts’ expectations of $80.34 billion. During the same period in the previous year, the firm earned $3.34 EPS. The business’s quarterly revenue was up 8.7% on a year-over-year basis. On average, equities research analysts forecast that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Friday, August 15th were issued a $0.55 dividend. The ex-dividend date of this dividend was Friday, August 15th. This represents a $2.20 dividend on an annualized basis and a yield of 0.7%. Cencora’s payout ratio is currently 22.63%.

Insider Buying and Selling

In related news, CEO Robert P. Mauch sold 5,097 shares of the business’s stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $326.80, for a total value of $1,665,699.60. Following the transaction, the chief executive officer directly owned 37,940 shares of the company’s stock, valued at approximately $12,398,792. The trade was a 11.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Chairman Steven H. Collis sold 31,350 shares of the business’s stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total value of $9,087,111.00. Following the completion of the transaction, the chairman directly owned 305,913 shares in the company, valued at approximately $88,671,942.18. This represents a 9.30% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 41,544 shares of company stock worth $12,230,941. 10.80% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Wells Fargo & Company boosted their price target on Cencora from $337.00 to $354.00 and gave the company an “overweight” rating in a research note on Wednesday, August 13th. Morgan Stanley set a $330.00 price target on Cencora and gave the company an “equal weight” rating in a research note on Wednesday, July 16th. Evercore ISI set a $340.00 price target on Cencora in a research note on Wednesday, October 8th. Weiss Ratings restated a “buy (b-)” rating on shares of Cencora in a research note on Thursday. Finally, UBS Group boosted their price target on Cencora from $350.00 to $380.00 and gave the company a “buy” rating in a research note on Monday, October 27th. Nine analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $329.55.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.